| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prevalence of cardiovascular risk factors in patients with psoriasis.
|
J Am Acad Dermatol
|
2006
|
4.12
|
|
2
|
Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database.
|
Eur Heart J
|
2009
|
3.93
|
|
3
|
Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study.
|
BMJ
|
2013
|
3.22
|
|
4
|
Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
|
Ann Intern Med
|
2012
|
3.14
|
|
5
|
The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.
|
J Am Acad Dermatol
|
2008
|
2.95
|
|
6
|
The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.
|
Arch Dermatol
|
2010
|
2.90
|
|
7
|
Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom.
|
J Invest Dermatol
|
2011
|
2.36
|
|
8
|
National Psoriasis Foundation clinical consensus on disease severity.
|
Arch Dermatol
|
2007
|
2.29
|
|
9
|
Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006.
|
Arch Dermatol
|
2010
|
2.29
|
|
10
|
Psoriasis and metabolic disease: epidemiology and pathophysiology.
|
Curr Opin Rheumatol
|
2008
|
2.25
|
|
11
|
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.
|
J Am Acad Dermatol
|
2008
|
2.19
|
|
12
|
Increased risk for demyelinating diseases in patients with inflammatory bowel disease.
|
Gastroenterology
|
2005
|
2.15
|
|
13
|
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.
|
J Am Acad Dermatol
|
2011
|
2.03
|
|
14
|
Attributable risk estimate of severe psoriasis on major cardiovascular events.
|
Am J Med
|
2011
|
1.94
|
|
15
|
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.
|
J Am Acad Dermatol
|
2009
|
1.94
|
|
16
|
Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system.
|
JAMA Dermatol
|
2013
|
1.88
|
|
17
|
Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study.
|
Arch Dermatol
|
2011
|
1.88
|
|
18
|
Immunosuppressant medications and mortality in inflammatory bowel disease.
|
Am J Gastroenterol
|
2008
|
1.80
|
|
19
|
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
|
J Am Acad Dermatol
|
2009
|
1.76
|
|
20
|
Psoriasis severity and the prevalence of major medical comorbidity: a population-based study.
|
JAMA Dermatol
|
2013
|
1.64
|
|
21
|
Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients.
|
J Invest Dermatol
|
2007
|
1.64
|
|
22
|
Obesity and the risk of psoriatic arthritis: a population-based study.
|
Ann Rheum Dis
|
2012
|
1.63
|
|
23
|
The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.
|
J Am Acad Dermatol
|
2011
|
1.59
|
|
24
|
AJC editor's consensus: psoriasis and coronary artery disease.
|
Am J Cardiol
|
2008
|
1.54
|
|
25
|
Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses.
|
J Am Acad Dermatol
|
2013
|
1.49
|
|
26
|
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.
|
J Am Acad Dermatol
|
2009
|
1.48
|
|
27
|
Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis.
|
Arch Dermatol
|
2012
|
1.37
|
|
28
|
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.
|
J Am Acad Dermatol
|
2007
|
1.35
|
|
29
|
Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis.
|
Atherosclerosis
|
2012
|
1.29
|
|
30
|
Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.
|
J Am Acad Dermatol
|
2012
|
1.21
|
|
31
|
Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients.
|
J Am Acad Dermatol
|
2011
|
1.18
|
|
32
|
Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts.
|
J Am Acad Dermatol
|
2005
|
1.16
|
|
33
|
Prevalence and treatment patterns of psoriatic arthritis in the UK.
|
Rheumatology (Oxford)
|
2012
|
1.15
|
|
34
|
Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study.
|
Rheumatology (Oxford)
|
2013
|
1.11
|
|
35
|
Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study.
|
Ann Rheum Dis
|
2012
|
1.08
|
|
36
|
Consensus guidelines for the management of plaque psoriasis.
|
Arch Dermatol
|
2012
|
1.06
|
|
37
|
Update on the epidemiology and systemic treatment of psoriasis.
|
Expert Rev Clin Immunol
|
2007
|
1.05
|
|
38
|
Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network.
|
Pharmacoepidemiol Drug Saf
|
2014
|
1.04
|
|
39
|
HIV-positive patients in Botswana state that mobile teledermatology is an acceptable method for receiving dermatology care.
|
J Telemed Telecare
|
2011
|
1.00
|
|
40
|
Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009.
|
Pharmacoepidemiol Drug Saf
|
2013
|
1.00
|
|
41
|
Long-term treatment for severe psoriasis: we're halfway there, with a long way to go.
|
Arch Dermatol
|
2007
|
1.00
|
|
42
|
Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12.
|
Clin Lymphoma Myeloma
|
2007
|
0.97
|
|
43
|
Methicillin-resistant Staphylococcus aureus colonization in children with atopic dermatitis.
|
Pediatr Dermatol
|
2008
|
0.96
|
|
44
|
Is there truly a risk of lymphoma from biologic therapies?
|
Dermatol Ther
|
2009
|
0.96
|
|
45
|
Update on the natural history and systemic treatment of psoriasis.
|
Adv Dermatol
|
2008
|
0.96
|
|
46
|
Surrogate end points for the treatment of diabetic neuropathic foot ulcers.
|
Diabetes Care
|
2003
|
0.96
|
|
47
|
Adverse cutaneous reactions to guggulipid.
|
J Am Acad Dermatol
|
2005
|
0.95
|
|
48
|
Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT).
|
J Vis Exp
|
2012
|
0.93
|
|
49
|
A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa.
|
J Am Acad Dermatol
|
2009
|
0.93
|
|
50
|
Dermatologist response rates to a mailed questionnaire: a randomized trial of monetary incentives.
|
J Am Acad Dermatol
|
2011
|
0.93
|
|
51
|
The epidemiology of sunburn in the US population in 2003.
|
J Am Acad Dermatol
|
2006
|
0.92
|
|
52
|
Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial.
|
J Am Acad Dermatol
|
2008
|
0.91
|
|
53
|
The epidemiology of atopic dermatitis.
|
Clin Dermatol
|
2003
|
0.91
|
|
54
|
Seeing red: flushing out instigators of niacin-associated skin toxicity.
|
J Clin Invest
|
2010
|
0.91
|
|
55
|
High prevalence of aquagenic wrinkling of the palms in patients with cystic fibrosis and association with measurable increases in transepidermal water loss.
|
Pediatr Dermatol
|
2012
|
0.90
|
|
56
|
Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort.
|
J Am Acad Dermatol
|
2013
|
0.89
|
|
57
|
Identification of risk factors for psoriatic arthritis: scientific opportunity meets clinical need.
|
Arch Dermatol
|
2010
|
0.89
|
|
58
|
Reliability and validity of a photographic method for measuring facial hair density in men.
|
Arch Dermatol
|
2011
|
0.88
|
|
59
|
OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis.
|
J Am Acad Dermatol
|
2013
|
0.87
|
|
60
|
Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors.
|
J Am Heart Assoc
|
2014
|
0.87
|
|
61
|
Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome.
|
J Am Acad Dermatol
|
2005
|
0.87
|
|
62
|
A comparison of vascular inflammation in psoriasis, rheumatoid arthritis, and healthy subjects by FDG-PET/CT: a pilot study.
|
Am J Cardiovasc Dis
|
2013
|
0.86
|
|
63
|
Psoriasis and psoriatic arthritis: a public health agenda.
|
Am J Prev Med
|
2013
|
0.84
|
|
64
|
Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
|
J Drugs Dermatol
|
2008
|
0.84
|
|
65
|
Test characteristics of high-resolution ultrasound in the preoperative assessment of margins of basal cell and squamous cell carcinoma in patients undergoing Mohs micrographic surgery.
|
Dermatol Surg
|
2008
|
0.83
|
|
66
|
Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma.
|
Leuk Lymphoma
|
2011
|
0.83
|
|
67
|
Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009.
|
J Rheumatol
|
2013
|
0.82
|
|
68
|
The impact of psoriasis on 10-year Framingham risk.
|
J Am Acad Dermatol
|
2012
|
0.82
|
|
69
|
Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study.
|
Am J Cardiovasc Dis
|
2012
|
0.81
|
|
70
|
Srcasm overexpression in psoriasis-insights into pathogenesis.
|
J Cutan Pathol
|
2007
|
0.81
|
|
71
|
Assessing long-term drug safety: lessons (re) learned from raptiva.
|
Semin Cutan Med Surg
|
2010
|
0.79
|
|
72
|
High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response.
|
Arch Dermatol
|
2011
|
0.79
|
|
73
|
Use of complementary and alternative medicine among adults with skin disease: results from a national survey.
|
J Am Acad Dermatol
|
2009
|
0.79
|
|
74
|
Complementary and alternative medicine for psoriasis: a qualitative review of the clinical trial literature.
|
J Am Acad Dermatol
|
2009
|
0.78
|
|
75
|
Cardiovascular comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting.
|
J Rheumatol
|
2013
|
0.77
|
|
76
|
CD8+ lymphoma in a patient with human immunodeficiency virus.
|
Arch Dermatol
|
2005
|
0.77
|
|
77
|
Curcuminoids activate p38 MAP kinases and promote UVB-dependent signalling in keratinocytes.
|
Exp Dermatol
|
2010
|
0.77
|
|
78
|
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by.
|
J Clin Aesthet Dermatol
|
2016
|
0.77
|
|
79
|
Epstein-Barr virus and human herpesvirus type 6 infection in patients with psoriasis.
|
Eur J Dermatol
|
2006
|
0.77
|
|
80
|
Effect of wax epilation before hair removal with a long-pulsed alexandrite laser: a pilot study.
|
Dermatol Surg
|
2003
|
0.75
|
|
81
|
Using Hawthorne effects to improve adherence in clinical practice: lessons from clinical trials--reply.
|
JAMA Dermatol
|
2013
|
0.75
|
|
82
|
Dermatologist preferences for treatments to compare in future randomized controlled comparative effectiveness trials for moderate to severe psoriasis.
|
Arch Dermatol
|
2012
|
0.75
|
|
83
|
Correlation Between Appropriate Use Criteria and the Frequency of Subclinical Spread or Reconstruction With a Flap or Graft for Melanomas Treated With Mohs Surgery With Melanoma Antigen Recognized by T Cells 1 Immunostaining.
|
Dermatol Surg
|
2016
|
0.75
|
|
84
|
A randomized, double-blind, placebo-controlled proof of concept trial of topical cidofovir, 1% and 3%, for the prevention of beard hair growth in men.
|
Arch Dermatol
|
2012
|
0.75
|
|
85
|
The pitfalls of a purely clinical definition of nephrogenic systemic fibrosis: comment on the article by Todd et al.
|
Arthritis Rheum
|
2008
|
0.75
|
|
86
|
Assessing Cutaneous Psoriasis Activity Using FDG-PET: Nonattenuation Corrected Versus Attenuation Corrected PET Images.
|
Clin Nucl Med
|
2015
|
0.75
|
|
87
|
Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis.
|
J Am Acad Dermatol
|
2012
|
0.75
|
|
88
|
The role of topical therapy for patients with extensive psoriasis.
|
Cutis
|
2007
|
0.75
|
|
89
|
A randomized, double-blind comparison of the total dose of 1.0% lidocaine with 1:100,000 epinephrine versus 0.5% lidocaine with 1:200,000 epinephrine required for effective local anesthesia during Mohs micrographic surgery for skin cancers.
|
J Am Acad Dermatol
|
2009
|
0.75
|
|
90
|
Exploring priority research areas in psoriasis and psoriatic arthritis from dermatologists' perspective: a report from the GRAPPA 2011 annual meeting.
|
J Rheumatol
|
2012
|
0.75
|